Notably, PSA density emerged as a statistically significant predictor of PSMA PET positivity (OR 6.35; 95% CI 1.82–10.88; p=0.006), reinforcing its role as a valuable biomarker in prostate cancer imaging and supporting its inclusion in future risk stratification models (16). This evidence concerns the gene FOLH1 and prostate cancer.